Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy?

VHT charges 0.09% versus 0.36% for PPH and holds 411 stocks versus just 26 for PPH, making it the lower-cost, more diversified healthcare ETF. PPH has the stronger trailing 1-year return at 21.9% versus 18.2% and a higher dividend yield of 2.06% versus 1.68%, but it also carries higher concentration risk with its top three holdings near 50% of assets. The article favors VHT for long-term defensive exposure due to its cheaper fee structure, smaller drawdown, and broader healthcare coverage.

Analysis

The key signal is not “healthcare is defensive,” but that the market is paying up for a narrow GLP-1/mega-cap pharma factor inside an ETF wrapper that is supposed to be diversified. That creates a crowded-ownership problem: if one or two mega-cap names stall, the entire concentrated vehicle can de-rate faster than the broader sector because flow-driven buyers are effectively underwriting single-name momentum. VHT is the better structural holder because it monetizes healthcare breadth without forcing investors to make an implicit call on a small set of blockbuster drugs.

Second-order, the higher yield in the pharma basket is partly a compensation mechanism for lower growth visibility and higher patent-cliff risk. Over the next 6-18 months, the bigger risk is not a healthcare recession trade; it is a sentiment unwind in the crowded winners if rates stay sticky and investors rotate from duration-like growth defensives into cash-generative balance sheets with less multiple sensitivity. In that scenario, the concentrated fund can underperform sharply even if sector fundamentals remain intact, because its factor exposure is more like a single-name momentum basket than an all-weather defensive sleeve.

The contrarian miss is that the broad fund’s lower yield may actually be a feature in a late-cycle environment: less payout today, but better reinvestment into innovation-rich subsectors and lower dependence on any one patent cycle. Meanwhile, the pharma-only basket is implicitly a bet that current drug pricing power and obesity franchise dominance persist without meaningful policy or competitive interference. That is a high bar over multiple years, especially if regulatory scrutiny, formulary pressure, or incremental competition compresses margins faster than consensus expects.

For the named constituents, the biggest beneficiaries of a broad-healthcare allocation are the diversified incumbents that can absorb R&D volatility and buy back stock without single-product risk. The main loser is the capital allocated to the concentrated pharma sleeve for purely income reasons; investors may be harvesting a modest yield pickup while taking disproportionately higher drawdown and concentration risk.

Key Decisions for Investors

• Long VHT / short PPH as a 6-12 month relative-value pair: expect lower drawdown and less factor crowding to dominate if healthcare leadership broadens beyond GLP-1 winners; target 5-8% relative outperformance for VHT with tight stop if pharma momentum accelerates again.
• Buy VHT on weakness rather than chasing PPH strength; use any 3-5% pullback to build a core position for 12+ months, with the thesis that diversification plus lower fees should compound better than concentrated yield.
• For income-seeking exposure, prefer single-name dividend quality in JNJ and ABBV over PPH: higher control over patent/regulatory risk, better buyback support, and less index-level concentration risk over the next 12 months.
• If rates stay elevated, avoid adding to PPH on strength; treat it as a momentum trade only and hedge with a short-dated call spread or a partial short in VHT/PHRMA proxy names if available, since crowded defensives can unwind quickly when leadership rotates.
• Set a 3-6 month catalyst watch on GLP-1 pricing/regulatory headlines and any formulary pushback: those are the most likely triggers for a de-rating in the concentrated pharma basket and the cleanest window to rotate into VHT.